Project Grant R01HL181491
Award Date 9/1/25
Completion Date 6/30/29
Dollars Obligated $709K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to investigate the role of the enzyme ROCK2 in Takotsubo cardiomyopathy (TCM) and its impact on cardiovascular risk. The $123,930 award, spanning December 2024 to November 2026, will enable the principal investigator to determine how ROCK2 in macrophages contributes to cardiac dysfunction in the acute phase of TCM and...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $654,207 to The Johns Hopkins University to conduct research on the role of thrombospondin-1 (TSP-1) in heart failure with preserved ejection fraction (HFPEF). The goal is to identify the mechanisms by which TSP-1 activation modulates cardiac fibrosis and remodeling in HFPEF, particularly in relation to sex-specific...
- This federal Project Grant award of $650,028, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project at the University of California, Los Angeles (UCLA) to investigate the role of phosphodiesterases in regulating cyclic AMP signaling, excitation-contraction coupling, and arrhythmias in heart failure. The key objectives are to determine the differential effects of phosphodiesterase 4D signaling on cardiac...
- This Project Grant award, totaling $499,585.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The University of Texas Health Science Center at Tyler. The project aims to develop a novel therapeutic strategy called "Two-Target Fibrinolytic Therapy" (T2FT) to increase the efficacy of empyema treatment. The research involves preclinical testing and optimization of a combination therapy using alteplase (ALT), a docking site...
- This $1,488,899 Project Grant award was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Young Therapeutics LLC, a pharmaceutical research and development company based in Pennsylvania. The funding supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, which target specific protein kinases to preserve myocardial tissue and cardiac function following myocardial infarction. The research aims to...
- This Project Grant award of $615,006.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to reclassify and determine the pathophysiology of variants of unknown/uncertain significance (VUS) in the TNNT2 gene, which encodes an essential component of the cardiac sarcomere. The key products and services to be delivered include: Comprehensive functional studies of 251 TNNT2 VUS using a human induced pluripotent stem cell-derived...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $694,754 to The Washington University to investigate the connections between genotype, molecular/cellular dysfunction, and small molecule treatments for key troponin cardiomyopathy mutations. The 5-year project aims to build a mechanistic understanding of how specific genetic mutations impact contractile function at the molecular, cellular, and tissue levels...
- The federal Project Grant award titled "Lysosomal Ionic Dysregulation in Heart Disease" was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Temple University-Of The Commonwealth System Of Higher Education in Philadelphia, PA. The $717,558 award, which runs from September 4, 2025 to June 30, 2030, will support research to investigate the role of the lysosomal two-pore channel (TPC2) in promoting cardiomyocyte death and impaired...
- The Project Grant award titled "STRESS-INDUCED TRNA-DERIVED SMALL RNAS IN CARDIAC FIBROSIS" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) in the amount of $739,474.00. The award, with a performance period from August 18, 2025 to May 31, 2030, supports research conducted by The General Hospital Corporation (Massachusetts General Hospital) to investigate the anti-fibrotic roles of a tRNA-derived small RNA (ASP-GTC-3'TDR) in...